Autophagy is a cellular catabolic process by which long-lived proteins and damaged organelles are degradated by lysosomes. Activation of autophagy is an important survival mechanism that protects cancer cells from various stresses, including anticancer agents. Recent studies indicate that pyrvinium pamoate, an FDA-approved antihelminthic drug, exhibits wide-ranging anticancer activity. Here we demonstrate that pyrvinium inhibits autophagy both in vitro and in vivo. We further demonstrate that the inhibition of autophagy is mammalian target of rapamycin independent but depends on the transcriptional inhibition of autophagy genes. Moreover, the combination of pyrvinium with autophagy stimuli improves its toxicity against cancer cells, and pretreatment of cells with 3-MA or siBeclin1 partially protects cells from pyrvinium-induced cell death under glucose starvation, suggesting that targeted autophagy addiction is involved in pyrvinium-mediated cytotoxicity. Finally, in vivo studies show that the combination therapy of pyrvinium with the anticancer and autophagy stimulus agent, 2-deoxy-D-glucose (2-DG), is significantly more effective in inhibiting tumor growth than pyrvinium or 2-DG alone. This study supports a novel cancer therapeutic strategy based on targeting autophagy addiction and implicates using pyrvinium as an autophagy inhibitor in combination with chemotherapeutic agents to improve their therapeutic efficacy. Autophagy is controlled by the cellular transduction pathways that interpret the status of cellular energy and nutrients, which allows a tightly regulated autophagic response to environmental perturbations. AMP-activated protein kinase (AMPK) triggers autophagy, whereas autophagy is inhibited by the mammalian target of rapamycin (mTOR).
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Autophagy is controlled by the cellular transduction pathways that interpret the status of cellular energy and nutrients, which allows a tightly regulated autophagic response to environmental perturbations. AMP-activated protein kinase (AMPK) triggers autophagy, whereas autophagy is inhibited by the mammalian target of rapamycin (mTOR). 2 Recent studies have suggested an important role of Vps34 complex in manipulating both initiation and maturation of autophagosomes. 3, 4 In normal physiological conditions, autophagy proceeds at a modest basal level in virtually all cells to carry out homeostatic functions such as protein and organelle turnover. In response to such diverse stimuli as starvation, genotoxic chemicals and pathogen infection, autophagy process is induced for the maintenance of cellular metabolism or for the clearance of aggregated proteins, damaged organelles and intracellular pathogens, thus facilitating cell survival. 5 Likewise, many anticancer agents are stressors requiring the autophagy response that assists the cancer cells to survive the crisis, and such cancer cells are in a state of 'autophagy addiction'. 6 The implication is that targeting autophagy addiction to block this important survival mechanism of cancer cells should be especially effective. 6, 7 Pyrvinium is an FDA-approved antihelminthic drug for the treatment of enterobiasis. 8 Recent studies have demonstrated that pyrvinium exerts potent toxicity against various cancer cell lines during glucose starvation and that pyrvinium decreases the viability of colon cancer cell lines and inhibits proliferation of myeloma cells. [9] [10] [11] In our study, we demonstrate that pyrvinium potently inhibits autophagy by suppressing the transcription of autophagy genes and that targeting autophagy addiction by pyrvinium shows effective anticancer activity both in vitro and in vivo.
Results
Pyrvinium inhibits autophagosome formation. To determine whether pyrvinium affects autophagy in mammalian cell lines, we first used HeLa cells stably expressing GFP-LC3. We observed a decrease in GFP-LC3 puncta formation in pyrvinium-treated HeLa cells (Figure 1a ), suggesting that autophagosome formation is inhibited by pyrvinium.
To confirm these results, we assessed LC3 by immunoblot analysis, as the amount of LC3-II is correlated with the extent of autophagosome formation.
12 LC3-II levels were reduced in HeLa cells treated with pyrvinium (Figure 1b) , thus confirming that pyrvinium inhibited autophagosome formation. To investigate if these effects were restricted only to HeLa cells, we next used several different types of mammalian cell lines to analyze levels of LC3. In all cell lines studied, the LC3-II levels declined in response to pyrvinium treatment (Figure 1c) , demonstrating a ubiquitous effect of pyrvinium on autophagosome formation. To analyze the effects of pyrvinium on the level of total LC3B protein, we used siAtg7 to abrogate the conversion of LC3-I to LC3-II, and pyrvinium was found to decrease the total LC3 protein levels in HeLa cells (Supplementary Figure 1) . Furthermore, we found that the inhibiton of autophagy by pyrvinium was dose-dependent with an IC 50 of 50 nM (Figure 1d ). Finally, because pyrvinium blocks the basal autophagosome formation, it is possible that it could also block the induced autophagosome formation. Indeed, when cells were subjected to starvation in combination with pyrvinium, the number of autophagic vacuoles significantly decreased compared with that of starvation treatment alone (Figure 1e ), indicating that pyrvinium could block starvation-induced Figure 1 Pyrvinium-induced autophagy arrest in mammalian cell lines. (a) GFP-LC3-expressing HeLa cells were treated with pyrvinium (30 nM) and vehicle control (1% DMSO) as indicated for 48 h. Quantitation on the right represents average GFP puncta per cell from three independent experiments±S.D.; 500 cells were analyzed per treatment condition. Scale bar, 20 mm. (b) GFP-LC3-expressing HeLa cells were treated as in a, and the cell lysates were analyzed by western blotting. (c) Four different cell lines as indicated were treated with pyrvinium (200 nM) and vehicle control (1% DMSO) for 24 h, and the cell lysates were analyzed by western blotting. (d) HeLa-GFP-LC3 cells were treated with vehicle control (1% DMSO) and indicated concentrations of pyrvinium for 48 h. The LC3 puncta were quantified. The image data were expressed as % of control vehicle treated cells from two independent experiments ± S.D., 500 cells were analyzed per treatment condition. (e) HeLa cells were treated with pyrvinium (30 nM) and vehicle control (1% DMSO) in glucose-free media and then processed for EM analysis. The inset permits visualization of clearer autophagic vacuoles indicated by arrows. Data represent mean ± S.E.M. from two independent experiments of at least 200 cells per sample. N, nucleus. Scale bar, 2 mm. Actin served as a loading control throughout. Band intensity was calculated using ImageJ software (National Institutes of Health, Bethesda, MD, USA), and the ratio of LC3-II/Actin expression was normalized and values are indicated. *Po0.05, **Po0.01 (unpaired t-test) autophagosome formation. Thus, the presence of pyrvinium inhibits both basal as well as starvation-induced autophagosome formation in mammalian cells.
Pyrvinium decreases autophagic flux. LC3 analysis is now widely used to evaluate autophagy activity. However, the levels of LC3-II at a certain time point do not represent autophagic flux, therefore, it is important to measure the amount of LC3-II delivered to lysosomes by comparing LC3-II levels in the presence and absence of lysosomal inhibitors. Furthermore, LC3-II itself is an autophagy substrate, making interpretation of the results of LC3 immunoblot problematic, and as a result decreased LC3-II levels could be a reflection of autophagy enhancement and not de novo autophagy inhibition. 13 To discriminate between these two possibilities, we analyzed autophagy in the presence of lysosomal inhibitors. Analysis of LC3-II levels in control cells showed increases in the amount of LC3-II when treated with NH 4 Cl (Figure 2a Figure 2b) led to increased LC3-II levels and an increased number of LC3 puncta (Figure 2c ) that were further enhanced by lysosomal inhibitors NH 4 Cl and bafilomycin as expected. However, we also observed that pyrvinium caused decreases both in LC3-II levels and the numbers of LC3 puncta compared with that of stimuli treatment alone in the presence or absence of lysosomal inhibitors. Thus, pyrvinium also inhibits stimuli-induced autophagic flux. These results were further confirmed by measuring the rate of delivery of autophagosomes to lysosomes using a tandem monomeric RFP-GFP-tagged LC3. 15 Starvation increased the numbers of both autophagosomes and autolysosomes, which were restored by pyrvinium to a level even lower than that of the control cells (Figure 2d ), indicating that pyrvinium inhibited the starvation-induced autophagic flux. Together, the data presented in Figures 1 and 2 provide strong evidence that pyrvinium inhibits autophagy in vitro.
Pyrvinium inhibits autophagy in vivo. To determine whether pyrvinium inhibits autophagy in vivo, we first investigated its effects on zebrafish. Studies in zebrafish larvae have demonstrated that alterations in LC3-II levels could be measured in the presence of NH 4 Cl, therefore allowing us to investigate in vivo changes in autophagic flux. 16, 17 We observed an increase in LC3-II levels in zebrafish larvae treated with NH 4 Cl (Figure 3a) . However, pyrvinium caused a significant decrease in LC3-II levels in the presence or absence of NH 4 Cl compared with the control, suggesting that pyrvinium inhibits autophagic flux in zebrafish larvae. We next used mice to examine whether pyrvinium inflicts the similar effects. Liver tissue was selected as an indicator because it is the best-characterized organ for changes in autophagic activity. 16 Starvation strongly increased hepatic LC3-II levels, suggesting autophagy induction, but this increase was significantly reduced when treated with pyrvinium ( Figure 3b ). Thus, pyrvinium inhibited starvation-induced autophagy in mice. This result was further verified by immunohistochemical analysis of cytoplasmic LC3 puncta in liver specimens (Figure 3c ). LC3 staining was generally weak in liver specimens from fed mice. However, in liver samples from starved mice, the presence of LC3 puncta was observed in the context of strong cytoplasmic staining, which was significantly recovered upon pyrvinium treatment. Interestingly, as predicted by our model, the increases in LC3-II levels in the intestine, heart and lung of starved mice were consistently reduced when treated with pyrvinium (Figure 3d ), indicating that the total autophagy activity in starved mice might be inhibited by pyrvinium. Taken together, our studies suggested that pyrvinium inhibits autophagy in vivo.
Regulation of autophagy by pyrvinium is AMPK/mTOR independent. Pyrvinium is a quinoline-derived cyanine dye; the red fluorescence of pyrvinium can be observed by using fluorescent microscopy. 10 We found that pyrvinium formed dot-like aggregates (Supplementary Figure 3a) . Pyrvinium aggregates did not colocalize with the lysosome marker LAMP-1 or autophagosome marker LC3, but with mitochondria markers cytochrome-c and V-DAC or MitoTracker fluorescence signal (Supplementary Figure 3b) , these data suggest that pyrvinium has a preferential localization in mitochondria. In the presence of carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP), a proton ionophore that abolishes the electrochemical gradient, a very small amount of pyrvinium aggregates was detected (Supplementary Figure 3c ). Moreover, similar results were obtained by incubating the HEK293 cells in a high K þ buffer that dissipates the plasma membrane potential (Supplementary Figure 3c) . These results suggested that the formation of pyrvinium aggregates within mitochondria is dependent on the presence of a negative sink inside mitochondria created by proton pumps. It has recently been reported that pyrvinium inhibits the mitochondrial respiratory chain complex I activity, leading to decreased ATP production in human myeloma/erythroleukemia cells. 11 We then analyzed the ATP levels in HeLa and HEK293 cells treated with pyrvinium. Cellular ATP levels were significantly decreased by pyrvinium in a concentration-dependent manner (Supplementary Figure 3d) . AMPK is activated by the phosphorylation of the a-subunit of AMPK after an increase in the intracellular AMP/ ATP ratio. 5 Decreased cellular ATP levels by pyrvinium activated AMPK in Hela and HEK293 cells (Supplementary Figure 3e) . mTOR has emerged as a key negative regulator of autophagy, and the activity of mTOR can be regulated by AMPK. 18 Activation of AMPK by pyrvinium inversely correlated with inhibition of the mTOR (Supplementary Figure 3e) . The inhibition of the mTOR pathway was further confirmed by the blocked phosphorylation status of both ribosomal protein subunit S6 and eIF4E-binding protein (4EBP1). Interestingly, we found that exogenous ATP added to the cells after the addition of the pyrvinium restored the activity of AMPK and Figure 3g) , suggesting that inhibition of autophagy by pyrvinium is AMPK independent. As mentioned above, even in the presence of rapamycin, an inhibitor of mTOR, pyrvinium suppresses autophagy ( Figures  2b and c) . Thus, inhibition of autophagy by pyrvinium is AMPK/mTOR independent.
Pyrvinium reduces the transcription of autophagyassociated genes. According to our observations, we speculated that the presence of an mTOR-independent mechanism was responsible for the control of autophagy by pyrvinium. To address this hypothesis, we next examined protein levels of the class 3 phosphatidylinositol kinase Vps34/p150/Beclin1/Atg14 complex 1 that regulates autophagy, independent of mTOR function. 19 Treatment with pyrvinium reduced the levels of Beclin1, Vps34, Atg14 and p150 in HeLa and HEK293 cells, and the effect of pyrvinium on the levels of Vps34 complex was strongly correlated with that of LC3-II (Figure 4a ), indicating that pyrvinium-mediated inhibition of autophagy was associated with reduction in Vps34 complex levels. To address how pyrvinium reduces the levels of Vps34 complex, we conducted a time course study in HeLa cells treated with pyrvinium and found that the appearance of decreased levels of Vps34 complex relatively needed longer time periods (Figure 4b, Supplementary  Figure 4a) ; this raises the possibility that pyrvinium does not promote the degradation of Vps34 complex. Therefore, we next treated HeLa cells with pyrvinium in the presence of cycloheximide (CHX). The addition of pyrvinium with CHX did not reduce the levels of Vps34 complexes compared with that of CHX treatment alone (Figure 4c ), suggesting that pyrvinium does not promote the degradation but impairs Figure 3 Pyrvinium inhibits autophagy in vivo. (a) Zebrafish larvae were treated with pyrvinium (200 nM) and vehicle control (1% DMSO) in the presence or absence of NH 4 Cl (20 mM) for 24 h. Zebrafish larvae were then homogenized in lysis buffer and processed for western blotting. The panels showed autophagic flux (change in LC3-II levels upon NH 4 Cl treatment). Values represented means normalized to actin from three independent experiments ± S.E.M. (b) Mice were divided into four groups. Two groups were treated with pyrvinium (10 mg/kg), whereas the other two groups were treated with vehicle control (5% CMC-Na) by oral gavage for 2 weeks. At the last 2 days, one of the control groups and one of the pyrvinium-treated groups were starved for 48 h. After killing, the liver was dissected and homogenized in lysis buffer before being analyzed by western blotting. The graph represented the mean results from five mice per group with control set to 100%. Error bars represent S.E.M. (c) Immunohistochemical detection of cytoplasmic LC3 puncta in liver specimens from mice treated as in b. Representative images were provided as indicated. Scale bars, 20 mm. Arrowheads depicted LC3 dots. (d) Intestine, heart and lung tissues from starved mice treated with pyrvinium or vehicle control (5% CMC-Na) were isolated and analyzed by western blotting. Actin served as a loading control throughout. Band intensity was calculated using ImageJ software, and the ratio of LC3-II/actin expression was normalized and values are indicated. NS, not significant. **Po0.01 (unpaired t-test) the production of Vps34 complexes. In an attempt to understand whether pyrvinium regulates the transcription of Vps34 complex components, we used real-time PCR to measure the mRNA levels in HeLa cells. The results showed that pyrvinium reduced the Vps34, Beclin1, p150 and Atg14 mRNA levels in a dose-dependent manner (Figure 4d ). Similar inhibitory effects were observed on LC3B, Atg7 and Atg5 (Supplementary Figure 4b) . However, in the presence of actinomycin, an inhibitor of DNA transcription, pyrvinium did not further decrease the mRNA levels of Beclin1 and LC3B (Supplementary Figure 4c) , suggesting that pyrvinium reduces the transcription of autophagy-associated genes. In previous studies, pyrvinium had been shown to specifically inhibit the transcription of target genes of Wnt signaling; in contrast, pyrvinium had no discernible effect on the transcriptional responses of four other major signaling pathways (TGFa, BMP4, IL-4 and Notch). 10 In this study, we found that the mRNA and protein levels of some metabolic associated genes (PKM2, PGAM1and GSK3b) and exogenous GFP expression did not change upon treatment of pyrvinium ( Supplementary Figures 4d and e) , suggesting pyrvinium as a negative transcriptional regulator of autophagy.
Pyrvinium combined with autophagy stimuli sensitizes cancer cells to apoptosis. To further characterize the biological effects of pyrvinium at the cellular level, we analyzed the cytotoxicity of pyrvinium in selected human cancer cell lines. Pyrvinium inhibited the growth (Figure 5a ) and clone formation (Figure 5b ) of HeLa and HCT116 cells in a dose-dependent manner, but did not significantly induce apoptotic cell death (Supplementary Figures 5a and b) . These results indicated that the main growth inhibition induced by pyrvinium was not due to induction of apoptosis. It has been reported that the anticancer activity of pyrvinium shows preferential cytotoxicity during glucose starvation. 9 Starvation is the most well-known conventional inducer of autophagy. To determine whether other autophagy stimuli could also enhance the cytotoxicity of pyrvinium against cancer cells, we treated HeLa cells with pyrvinium in the presence of glucose starvation, etoposide or Pseudomonas aeruginosa.
14,20 All three combined treatments caused dramatically enhanced cell death compared with pyrvinium treatment alone (Figure 5c ). Cells treated with pyrvinium in combination with autophagy stimuli showed apoptotic morphology (Figure 5d ), characteristic caspase 3 and PARP cleavage (Figure 5e ), and increases in the number of terminal transferase dUTP nick-end labeling (TUNEL)-positive cells (Supplementary Figure 5c) . Similar results were obtained with MCF7 and PANC1 cells (data not shown). LC3 immunoblot studies further confirmed that autophagy was triggered by autophagy stimuli and that the induced autophagy was inhibited by the addition of pyrvinium (Figure 5f ). To test whether enhanced cell death is due to targeted autophagy addiction, we treated HeLa cells with commonly used autophagy inhibition agents under starvation condition ( Supplementary Figures 5d and e) . Similar to pyrvinium treatment, all three autophagy inhibitors showed increased cytotoxicity under starvation condition compared with that of normal growth conditions, suggesting that targeting autophagy addiction promotes cancer cell death. We next examined the cell viability of HeLa cells pretreated with 3-MA or siBeclin1 and then administered with pyrvinium under starvation condition. Pretreatment of cells with 3-MA or siBeclin1 partially protected cells from pyrvinium-induced cell death under glucose starvation (Figures 5g and h) , suggesting that targeted autophagy addiction is involved in pyrviniummediated cytotoxicity. Thus, our data suggest that pyrvinium sensitizes cancer cells to apoptosis in combination with autophagy stimuli, and this effect can at least be partially attributed to targeting the autophagy addiction on which cell depends for survival under harsh environmental conditions. Pyrvinium combined with 2-deoxy-D-glucose displays more potent anticancer activity in vivo. To examine whether the combination therapy of a chemotherapeutic agent to induce autophagy and pyrvinium to target the aroused autophagy addiction would result in greater efficacy than either agent alone, we used the autophagy inducer 2-deoxy-D-glucose (2-DG) in combination with pyrvinium in a xenograft mouse model. 2-DG was reported to induce autophagy by therapeutic starvation. 21 We first tested the efficacy of combination treatments in vitro. Similar to treatment of pyrvinium under starvation condition, the combination of pyrvinium with 2-DG was more toxic against 4T1 cancer cells than either treatment alone ( Supplementary  Figures 6a and b) . As predicted, 2-DG-induced autophagy was inhibited by pyrvinium in 4T1 cells ( Supplementary  Figure 6c) . Pyrvinium, in combination with 2-DG, was clearly more effective in reducing tumor volume and weight (Figures 6a-c) . Immunohistochemical analysis of cytoplasmic LC3 puncta in tumor samples confirmed that the 2-DG-triggered autophagy was inhibited by pyrvinium (Figure 6d ), suggesting that pyrvinium targets autophagy addiction caused by 2-DG in these tumors. Massive activation of caspase 3 was observed in tumor samples upon combination treatment (Figure 6e ). In the experiment where treatment began when tumors were 600 mm 3 , the combination chemotherapy could also induce apoptosis, leading to a decrease of tumor size (Figure 6f, Supplementary Figure 7a) . Thus, the combination chemotherapy with pyrvinium and 2-DG showed more potent growth suppressive effects in vivo. Moreover, the combination treatment showed minimal toxic effects in normal animals ( Supplementary Figures 7b-g ). The modest effects on body weights and liver size appear to be related to the reported adverse effects of orally administered pyrvinium. 22 
Discussion
In this study, we identify pyrvinium as a potent small molecule inhibitor of autophagy with an IC 50 of 50 nM. Using zebrafish and mice to assess the effects of pyrvinium on autophagy in vivo, we found that pyrvinium decreases their autophagy levels.
We observed that pyrvinium localized to mitochondria and identified pyrvinium as a lipophilic cation. Lipophilic cations such as rhodamine-123 have been used to monitor mitochondrial membrane potential in a single living cell. 23 Thus, because of its innate fluorescent properties and low toxicities, pyrvinium could be used as a new probe for monitoring mitochondrial membrane potential. Pyrvinium accumulates preferentially in mitochondria and disrupts respiratory chain complex I, leading to decreased ATP production, which causes AMPK activation and downstream inhibition of mTOR. The inhibitory function of mTOR in autophagy is well established. 24 However, recent screens of FDA-approved drugs have identified numerous mTOR-independent autophagy modulators. 25 We show that pyrvinium decreases Vps34 complex levels by inhibiting the transcription of its components. In recent years there has been a rapid increase in reports on transcriptional regulation of autophagy. 26, 27 In a previous study, pyrvinium was shown to selectively bind to the minor groove of AT-rich DNA regions. 28 Whether this property of pyrvinium is associated with its We demonstrate that pyrvinium inhibits proliferation but does not cause significant apoptotic cancer cell death under normal physiological conditions; however, massive cell death occurs in response to pyrvinium when subjected to worse conditions such as starvation, genotoxic insult or pathogen infection. We speculate that under these conditions, cancer cells are in a state of autophagy addiction requiring the autophagic process for promoting cell survival, whereas this important survival pathway can be blocked by pyrvinium, thus generating the observed phenomenon of massive cancer cell death. Using chloroquine (CQ), 3-MA and siBeclin1 to inhibit autophagy, elevated numbers of cancer cells die under starvation conditions compared with normal conditions. These observations support a role of targeting autophagy addiction by pyrvinium treatment to promote cancer cell death. However, except for its function as an autophagy inhibitor, pyrvinium has multiple other roles. 10, 29, 30 It has also been shown that the suppression of unfolded protein responses is involved in pyrvinium-mediated cytotoxicity under glucose starvation 29 ; whether inhibited Wnt signaling and androgen receptor activity could also contribute to these effect is unclear. Although future research studies are required to provide more direct evidence for the above conclusions, there is no doubt that autophagy inhibition by pyrvinium partially contributes to cancer cell death in the context of targeting autophagy addiction.
The notion of autophagy modulation as a potential therapeutic target for cancer has been recently discussed in the literature. [31] [32] [33] [34] [35] Accordingly, there are several Phase I/II clinical trials in progress using the lysosome inhibitors CQ or hydroxychloroquine in combination with chemotherapeutic agents for the treatment of some tumors. 34 As pyrvinium is determined as a potent autophagy inhibitor, we studied its use as a cancer treatment in vivo to target autophagy addiction. To create the state of autophagy addiction in cancer, 2-DG was selected because it induces autophagy by therapeutic starvation. 21 Moreover, 2-DG appears to be safe when administered to animals. 36 Xenograft experiments demonstrated that pyrvinium combination therapy with 2-DG shows significantly enhanced anticancer efficacy in vivo, supporting our hypothesis of targeting autophagy addiction by pyrvinium in cancer. In addition, the combination therapy, which exhibits minimal toxicity in normal animals, appears to be a promising cancer-treatment candidate.
As discussed earlier, many open questions and controversies remain regarding autophagy as a target of pyrvinium in cancer therapy. Although the available data support the concept that cancer cells undergoing increased autophagy die in response to pyrvinium, no direct evidence have unequivocally demonstrated that the synergistic inhibition of 4T1 tumor growth by the combination of pyrvinium and 2-DG arises specifically from autophagy inhibition. However, given the strong potential of pyrvinium as a lead compound for developing specific and potent autophagy inhibitor, screening out the pyrvinium derivatives without autophagy-independent functions would help us to further elucidate the existing paradigms that dictate our current understanding of autophagy as a target in cancer therapy.
Materials and Methods
Cell culture and treatment. HeLa, HeLa-GFP-LC3, HEK293, PANC1, HCT116 and MEF cells were cultured in Dulbecco's modified Eagle's medium Antibodies and reagents. Rabbit polyclonal antibody anti-LC3 was from Novus (Littleton, CO, USA). Rabbit polyclonal antibody anti-Vps34 and rabbit monoclonal antibody anti-p150 and anti-Cleaved caspase 3 were from Cell Signaling (Beverly, MA, USA). Rabbit polyclonal antibody anti-Atg14, anti-Beclin1, anti-UVRAG, anti-Atg5, anti-Atg7, anti-PKM2, anti-PGAM1 and anti-GSK3b were from MBL (Nagoya, Japan). Rabbit polyclonal antibody anti-AMPKa, anti-phosphoAMPKa, anti-mTOR, anti-phospho-mTOR, mouse monoclonal antibody anticaspase 3, anti-PARP and anti-GFP were from Millipore (Bedford, MA, USA). Rabbit polyclonal antibody anti-4EBP1, anti-phospho-4EBP1, anti-S6K, antiphospho-S6K and mouse monoclonal antibody anti-b-actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Pyrvinium pamoate was from US Pharmacopeia (Rockville, MD, USA). Pepstatin A, E64d, rapamycin, CHX, etoposide, CQ, bafilomycin, FCCP, ATP, MitoTracker green, compound C and 2-DG were from Sigma (St. Louis, MO, USA).
Tissue and cell lysates and western blotting. Tissue samples were homogenized in lysis buffer (50 mM Tris-base, 1.0 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% TritonX-100, 1% sodium deoxycholate and 1 mM phenylmethylsulfonyl fluoride). After centrifugation at 5000 Â g for 5 min, the supernatant fractions were collected. Cells were solubilized in lysis buffer for 1 h at 4 1C and lysates were centrifuged at 5000 Â g for 20 min. Total homogenates were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Amersham Biosciences, Piscataway, NJ, USA) as previously described. 37 Upon incubation with primary and secondary antibodies, immunoreactive bands were detected by ECL according to the manufacturer's instructions.
Immunohistochemistry. Immunohistochemistry was performed using the Dako EnVision Systems (Dako Cytomation GmbH, Hamburg, Germany). 38 Consecutive paraffin wax-embedded tissue sections (3-5 mm) were dewaxed and rehydrated. Antigen retrieval was performed by pretreatment of the slides in citrate buffer (pH 6.0) in a microwave oven for 12 min. Thereafter, slides were cooled to room temperature in deionized water for 5 min. Endogenous peroxidase activity was quenched by incubating the slides in methanol containing 0.6% hydrogen peroxide followed by washing in deionized water for 3 min after which the sections were incubated for 1 h at room temperature with normal goat serum and subsequently incubated at 4 1C overnight with the primary antibodies rabbit anti-LC3 (diluted 1 : 200) or anti-Cleaved caspase 3 (diluted 1 : 500). Next, the sections were rinsed with washing buffer (TBS with 0.1% bovine serum albumin) and incubated with horseradish peroxidase-linked goat anti-rabbit antibodies followed by reaction with diaminobenzidine and counterstaining with Mayer's hematoxylin. Immunostaining was detected using 3,3 0 -diaminobenzidine substrate solution (Dako Cytomation GmbH) according to the manufacturer's instructions.
Electron microscopy. Pretreated cells were fixed in 0.1% glutaraldehyde, dehydrated and embedded. Ultrathin sections (70 nm) were cut, stained and analyzed by a Philips EM420 electron microscopy (Philips instruments, Inc., Mahwah, NJ, USA).
ATP measurement. Cells were incubated with pyrvinium for 24 h, and the cell suspension was transferred to a 96-well microplate (BD Biosciences, San Jose, CA, USA). Cellular ATP levels were examined using an ATP Assay Kit (Invitrogen).
Real-time PCR. Total cellular RNA was isolated with TRIzol (Invitrogen). cDNA synthesis was performed using Improm-II Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. The Vps34 mRNA was assayed using the primers sense: 5 0 -GGACCTTCTGACCACGAT-3 0 and antisense: Bacteria strains. P. aeruginosa strain PAO1 wild-type (WT) was a gift from Stephen Lory (Harvard Medical School, Boston, MA). Bacteria were grown overnight in Luria-Bertani (LB) broth at 37 1C with vigorous shaking. The next day, the bacteria were pelleted by centrifugation at 8000 Â g and resuspended in 10 ml of fresh LB broth, in which they were allowed to grow until the mid-logarithmic phase. Thereafter, the optical density (OD) at 600 nm was measured, and the density was adjusted to 0.25 OD (0.1 OD ¼ 1 Â 10 8 cells/ml). Cells were washed once with PBS after overnight culture in serum-containing medium and changed to serum-free and antibiotic-free medium immediately before infection.
Cell proliferation, viability and apoptotic cell death measurement. Cells were seeded onto 96-well microplates and treated with pyrvinium. After several days of incubation, cell proliferation was evaluated by the WST-8 colorimetric assay using a Cell Count Reagent SF reagent (Nacalai Tesque, Kyoto, Japan). Cell viability was analyzed by MTT assay as previously described. 39 Apoptosis was measured by TUNEL assay as previously described.
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Zebrafish and mouse experiments. Autophagy assays in these animals were performed as previously described. 17 The Institutional Animal Care and Treatment Committee of Sichuan University approved all studies herein. Briefly, after the determination of maximum tolerated concentration of pyrvinium in larval zebrafish, endogenous LC3-II assays were performed at the following concentrations: NH 4 Cl at 100 mM and pyrvinium at 200 nM for 24 h. WT larvae (n ¼ 30 per treatment group) at 2 d.p.f. were exposed to pyrvinium or embryo medium (untreated control) for 20 h before compound replenishment and the addition of NH 4 Cl. Larvae were incubated in compounds for a further 4 h, homogenized in lysis buffer, processed for western blotting as described above. For mouse experiments, 20 healthy female mice (BALB/c, 6-8 weeks of age, nonfertile and 18-20 g each) were used at the start of the study. The mice were divided into four groups. After 2 weeks of acclimatization, two groups were treated with pyrvinium (10 mg/kg), whereas the other two groups were treated with vehicle control (5% CMC-Na) by oral gavage for 2 weeks. At the last 2 days, one of the control groups and one of the pyrvinium-treated groups were starved for 48 h. After killing, the liver was dissected and homogenized in lysis buffer before being analyzed by western blotting.
Tumor xenograft model. Healthy female mice (BALB/c, 6-8 weeks of age, nonfertile and 18-20 g each) were injected subcutaneously with 4T1 cells (one million cells per mouse). When tumors were approximately 50 or 600 mm 3 in size, the animals were pair-matched into four groups (eight mice per group) as follows: 5% CMC-Na-treated control, 2-DG alone, pyrvinium alone and pyrvinium þ 2-DG. At day 0, the 2-DG alone and pyrvinium þ 2-DG groups received 0.2 ml of 2-DG i.p. at 150 mg/ml (1000 mg/kg), which was repeated every 2 days for the duration of the experiment. On day 1, the pyrvinium and pyrvinium þ 2-DG groups received 0.2 ml of pyrvinium i.g. at 1 mg/ml (10 mg/kg), which was repeated once a day. This experiment was then repeated (n ¼ 3/group) but was delayed until the tumors were approximately 1000 mm 3 . Tumor measurements were taken by caliper every 3 days and converted to tumor volume by using the formula W Â L 2 /2. At the time of killing, tumors were excised, pictured and weighed.
Toxicity assessment. BALB/c female mice, six animals per group, were dosed as described in tumor xenograft model experiment. Body weight was determined every 3 days until the end of the study. At the time of killing, tissues were harvested, weighted and prepared for H&E staining.
